Abstract YO25
Case summary
Background
Pembrolizumab is an immune checkpoint inhibitor, approved in recurrent head and neck cancer. Its use has been associated with hyperprogression, a phenomenon of extraordinarily rapid tumor progression in patients undergoing immunotherapy. Here, we report a case that showed hyperprogression after pembrolizumab in recurrent oropharyngeal cancer and the use of nab-paclitaxel as salvage treatment.
Methods
The patient was a 70 years old man with recurrent base of tongue cancer, who had progressed 2 months after receiving 2 cycles of cisplatin and 5-fluorouracil, followed by concurrent chemoradiotherapy (70Gy in 35 fractions over 7 weeks).
PD-L1 testing was done, which expressed 1-50% membrane positivity. He received second line treatment of intravenous Pembrolizumab 100mg, administered 3 weekly.
Clinical and radiological assessments were done, comparing the baseline CT scan and the CT scan after immunotherapy. Hyperprogression was confirmed by measuring the tumor growth kinetics (TGK). Hyperprogression is defined as a TGK ratio >2 with rapid progression.
The patient was started on intravenous nab-paclitaxel(125mg/m2), carboplatin (AUC 2.5), and bevacizumab (100mg) weekly for 2 weeks, administered 3 weekly after confirmation of hyperprogression with pembrolizumab treatment.
Results
14 days after the administration of the first cycle of Pembrolizumab, patient developed bigger tongue swelling, occupying the whole oral cavity protruding beyond the lips. Hyperprogression was confirmed with a CT scan, where a larger tongue mass was observed (67% enlargement) with new lung lesions and a TGK of 3.
Patient review 3 weeks after cycle 1 of nab-paclitaxel, carboplatin and bevacizumab showed smaller tongue swelling. He was given a total of 3 cycles of chemotherapy but acquired neutropenia and pneumonia after cycle 2 and tumor bleed after cycle 3. He died of the disease 110 days after receiving his chemotherapy.
Conclusion
It is important to be aware that hyperprogression can occur early in the treatment using pembrolizumab. If used judiciously, nab-paclitaxel can be effective as salvage treatment in hyperprogression of oropharyngeal cancer.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
133P - Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
134P - Identification, development and validation of a circulating miRNA-based diagnostic signature for early detection of gastric cancer
Presenter: Daisuke Izumi
Session: Poster display session
Resources:
Abstract
135P - The promising key genes associated with tumour microenvironment and prognosis of hepatocellular carcinoma
Presenter: Jing Fang
Session: Poster display session
Resources:
Abstract
136P - Helicobacter pylori-positive gastric diffuse large B-cell lymphoma: A subset with distinct prognostic features
Presenter: Yuan Cheng
Session: Poster display session
Resources:
Abstract
137P - Significant benefit of pyrotinib combined with SHR6390 in patients with multiline-resistant HER2-positive advanced gastric cancer
Presenter: Zuhua Chen
Session: Poster display session
Resources:
Abstract
138P - Incidence of supracarinal lymph node positivity in operated cases of total esophagectomy: Short term results from a tertiary cancer centre
Presenter: Akhil Palod
Session: Poster display session
Resources:
Abstract
139P - Prognostic usefulness of advanced lung cancer inflammation index in locally-advanced pancreatic carcinoma patients treated with radical chemoradiotherapy
Presenter: Ayberk Besen
Session: Poster display session
Resources:
Abstract
140P - Pancreaticoduodenectomy versus combined neoadjuvant chemotherapy and pancreaticoduodenectomy: Survival patterns among patients with stage II & III periampullary carcinoma
Presenter: Mai Abdelkader
Session: Poster display session
Resources:
Abstract
141P - A 13-gene signature of DNA repair predicts prognosis in gastric cancer patients
Presenter: Jinjia Chang
Session: Poster display session
Resources:
Abstract
142P - Relation between Interleukin -4 (590C/T) gene polymorphism and hepatocellular carcinoma risk in HBV and HCV patients
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract